NDP Stats & Data

Nitazene opioids are frequently implicated in severe poisonings due to extreme potency and unexpected appearance in unregulated supplies, including fake medicines that mimic oxycodone/benzodiazepines; this raises overdose risk, especially in people without opioid tolerance. Naloxone reverses nitazene overdoses, but multiple sequential doses may be needed; always call emergency services and continue rescue breathing while awaiting help. Fentanyl test strips do not detect nitazenes, so a negative FTS does not rule out presence of NDP or other nitazenes. Drug checking services report nitazenes appearing where they are not expected (e.g., samples sold as oxycodone); treat all unknown powders/pills as potentially containing high‑potency opioids. Co‑exposure to other sedatives (illicit benzodiazepines) or veterinary α2‑agonists (e.g., xylazine, medetomidine) is increasingly common and can blunt response to naloxone or prolong sedation; airway support and medical care are critical even after naloxone. Because nitazenes may be present at very low concentrations, routine test kits and many FTS will miss them; laboratory drug checking is preferable where available. Doses at the microgram scale require calibrated equipment; volumetric dosing is strongly preferred to reduce measurement error. Avoid rapid redosing—some users report cumulative sedation with nitazenes over hours, increasing the risk of delayed respiratory depression. Given market variability and absent human pharmacokinetic data for NDP specifically, treat potency and duration as uncertain, start well below any published ranges, and avoid mixing with other depressants.